Current Report Filing (8-k)
June 05 2018 - 6:16AM
Edgar (US Regulatory)
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
Form
8-K
CURRENT
REPORT
Pursuant to Section 13 or 15(d)
of the Securities Exchange Act of 1934
Date of Report (Date of earliest event reported): June 4, 2018
Dynavax Technologies Corporation
(Exact name of registrant as specified in its charter)
Commission
File
Number: 001-34207
|
|
|
Delaware
|
|
33-0728374
|
(State or other jurisdiction
of incorporation)
|
|
(IRS Employer
Identification No.)
|
2929 Seventh Street, Suite 100
Berkeley, CA 94710-2753
(Address of principal executive offices, including zip code)
(510)
848-5100
(Registrants telephone number, including area code)
(Former name or former address, if changed since last report)
Check the appropriate box below if the Form
8-K
filing is intended to simultaneously satisfy the filing obligation
of the registrant under any of the following provisions:
☐
|
Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
|
☐
|
Soliciting material pursuant to Rule
14a-12
under the Exchange Act (17 CFR
240.14a-12)
|
☐
|
Pre-commencement
communications pursuant to Rule
14d-2(b)
under the Exchange Act (17 CFR
240.14d-2(b))
|
☐
|
Pre-commencement
communications pursuant to Rule
13e-4(c)
under the Exchange Act (17 CFR
240.13e-4(c))
|
Indicate by check mark whether the Registrant is an emerging growth company as
defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule
12b-2
of the Securities Exchange Act of 1934
(§240.12b-2
of this chapter).
Emerging growth company
☐
If an emerging growth company, indicate by check mark if the Registrant has elected not to use the extended transition period for complying with any new or
revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.
☐
On June 4, 2018, Dynavax Technologies Corporation, a Delaware corporation
(Dynavax), issued a press release and presented a corresponding poster and investor presentation announcing data from its ongoing Phase 1b/2 study investigating
SD-101,
Dynavaxs intratumoral
TLR9 agonist, in combination with KEYTRUDA
®
(pembrolizumab), an
anti-PD-1
therapy developed by Merck &
Co., Inc. (known as MSD outside the United States and Canada) in patients with advanced melanoma at the 2018 American Society of Clinical Oncology Annual Meeting, in Chicago, IL. A copy of the press release, the poster and the investor presentation
are filed as Exhibits 99.1, 99.2 and 99.3 to this Current Report on Form
8-K
and are incorporated herein by reference.
Item 9.01.
|
Financial Statements and Exhibits.
|
(d)
Exhibits
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by
the undersigned hereunto duly authorized.
|
|
|
|
|
|
|
|
|
Dynavax Technologies Corporation
|
|
|
|
|
|
|
|
|
Date: June 4, 2018
|
|
By:
|
|
/s/ STEVEN N. GERSTEN
|
|
|
|
|
Steven N. Gersten
|
|
|
|
|
Vice President, General Counsel and
Chief
Ethics and Compliance Officer
|
Dynavax Technologies (NASDAQ:DVAX)
Historical Stock Chart
From Sep 2024 to Oct 2024
Dynavax Technologies (NASDAQ:DVAX)
Historical Stock Chart
From Oct 2023 to Oct 2024